China-based Jacobio Pharma (HKG: 1167) has announced clinical results for its novel KRAS G12C inhibitor, glecirasib, in the treatment of KRAS G12C mutant advanced colorectal cancer (CRC). The findings were presented at the Second JCA-AACR Precision Medicine International Conference, showcasing the potential of glecirasib as both a monotherapy and in combination with cetuximab.
Monotherapy Study Outcomes
In the monotherapy study, glecirasib demonstrated an overall response rate (ORR) of 33.3% (11 out of 33 patients), a disease control rate (DCR) of 90.9% (30 out of 33 patients), and a median progression-free survival (mPFS) of 6.9 months. These results indicate the drug’s potential efficacy in treating patients with advanced CRC.
Combination Therapy with Cetuximab
In a trial combining glecirasib with cetuximab, the ORR was even more promising at 62.8% (27 out of 43 patients), with a DCR of 93% (40 out of 43 patients). The mPFS for this combination therapy was not reached at the data cutoff date of May 23, 2023, suggesting a potentially longer duration of effectiveness. The majority of treatment-related adverse events were grades 1-2, indicating a manageable safety profile.
Glecirasib’s Development Pipeline
Glecirasib, an in-house novel KRAS G12C inhibitor developed by Jacobio, is under evaluation in a number of Phase I/II clinical trials across China, the United States, and Europe. These trials are assessing the drug’s efficacy in patients with advanced solid tumors harboring the KRAS G12C mutation, including a pivotal clinical trial in non-small cell lung cancer (NSCLC) in China, a monotherapy study for STK11 co-mutated NSCLC in the front-line setting, and combination therapy trials with SHP2 inhibitor JAB-3312, anti-PD-1 antibody, and cetuximab.-Fineline Info & Tech
